Ibogaine molecule:

Image from PubChem

Ibogaine Clinical Trials

Ibogaine to Determine Maximum Tolerated Dose (MTD) or Treat-to-Target Dose (TTD) for the Evaluation of Efficacy and Safety

To see complete record on clinicaltrials.gov, please visit this link

Id: NCT05029401

Organisation Name: DemeRx IB, Inc.

Overal Status: Recruiting

Start Date: April 1, 2021

Last Update: August 2, 2022

Lead Sponsor: DemeRx IB, Inc.

Brief Summary: Study DMX-IB 201 is a Phase 1/2a study of ibogaine consisting of an initial single ascending dose escalation stage to determine the maximum tolerated dose (MTD) or treat-to-target dose (TTD) in healthy volunteers, followed by a randomized, double-blind, placebo-controlled proof of concept stage to demonstrate the efficacy, safety and tolerability of the selected dose in opioid-dependent patients who seek medically supervised opioid withdrawal

  • Opiate Withdrawal Syndrome

Total execution time in seconds: 0.28980779647827